PRO 01

Drug Profile

PRO 01

Alternative Names: PRO-01

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator Prothix
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Thromboembolism

Most Recent Events

  • 20 Jul 2016 Preclinical trials in Thromboembolism in Netherlands (unspecified route)
  • 20 Jul 2016 PRO 01 is available for licensing - http://prothix.com/strategy/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top